Kewang Pharmaceutical's ESMO Asia Oral Report Announces Outstanding Data for Phase I of the World's First ES014 Monotherapy

Zhitong Finance App learned that on December 5, 2025, Kewang Pharmaceutical announced the phase I clinical trial results of its self-developed bispecific antibody ES014 through an oral report at the European Society of Medical Oncology Asian Annual Meeting (ESMO Asia).

ES014 is the world's first CD39/TGFbeta bispecific antibody independently developed by Kewang Pharmaceutical, and is also the world's first CD39/TGFbeta bispecific antibody to enter the clinical stage. It has shown initial and clinically significant anti-tumor activity in a number of tumor types that have not met clinical needs. Research results show that ES014 has an ORR of 40% and a DCR of 100% in the treatment of sclerofibroma (DT), providing a promising innovative treatment direction; in non-small cell lung cancer (NSCLC), ES014 shows initial efficacy in patients with high CD39 expression, laying the foundation for accurate drug use strategies; in addition, it is worth noting that ES014 may bring new treatment options for patients with very limited clinical treatment options.

As core pipelines such as ES014 have shown initial clinical benefits, and the world's scarce myeloid cell connector MCE platform has been built. As a Kewang medicine that is deeply involved in immunology and focuses on research and innovation, the certainty of implementing its value will become increasingly higher, and the potential for external licensing and cooperation in the international market will gradually become apparent. From the perspective of the long-term value of the innovative drug industry, once the clinical value of the innovation pipeline is recognized internationally, the sustainability of cash flow is expected to shift from “financing-driven” to “transaction-driven and cooperation-driven”.